Business Context and Reporting Period
Company: Advanced Biomed Inc. (ADVB)
Filing Type: Form 8-K (Current Report)
Date of Report: January 16, 2026 (Updated January 21, 2026)
Context: The filing addresses a Notice of Delisting from The Nasdaq Capital Market due to failure to meet the Minimum Bid Price Requirement of $1.00 per share.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
- Delisting Notice: On January 16, 2026, Nasdaq notified the Company that its securities would be scheduled for delisting and suspended on January 27, 2026, as the stock price remained below $1.00 after the 180-day compliance period ended on January 14, 2026.
- Appeal Filed: On January 21, 2026, the Company submitted a hearing request to the Nasdaq Hearings Panel, which stayed the suspension pending a decision.
- Remediation Plan: The Company intends to present a plan to regain compliance, centered on a reverse stock split approved by stockholders on January 12, 2026, expected to become effective on or after February 13, 2026.
Outlook, Risks, and Contingencies
- Uncertainty of Outcome: There is no assurance that the Hearings Panel will grant the request for continued listing or that the Company will evidence compliance within any granted timeframe.
- Forward-Looking Statements: The Company disclaims any obligation to update statements regarding its intent to regain compliance, noting that actual results may differ materially due to risks and uncertainties.
Investor Verification Checklist
- Verify the status of the reverse stock split approval and its expected effective date (on or after February 13, 2026).
- Monitor the Nasdaq Hearings Panel decision regarding the appeal filed on January 21, 2026.
- Confirm whether the stock price will meet the $1.00 minimum bid price requirement post-split.
- Check for any subsequent filings regarding the suspension date of January 27, 2026, should the appeal be denied.